Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer

被引：1
|
作者：
Nozawa, Kazuki [1 ]
Sawaki, Masataka [1 ]
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 03期
关键词：
OPEN-LABEL;
D O I：
10.1016/S1470-2045(23)00014-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E103 / E103
页数：1
相关论文
共 50 条
  • [31] New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
    Brett, Jamie O.
    Mayer, Erica L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 594 - 610
  • [32] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [33] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [34] Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer
    Lopez, M.
    Di Lauro, L.
    Viola, G.
    Foggi, P.
    Conti, F.
    Corsetti, S.
    Sergi, D.
    Botti, C.
    Di Filippo, F.
    Vici, P.
    CLINICA TERAPEUTICA, 2009, 160 (06): : 481 - 488
  • [35] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy
    Davie, Alison
    Traore, Sory
    Giovannitti, Massimo
    Pompilio, Giuseppe
    Lambton, Mark
    Cakar, Esra
    Chatterjee, Anuja
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 62 - 69
  • [36] Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
    Paluch-Shimon, Shani
    Neven, Patrick
    Huober, Jens
    Cicin, Irfan
    Goetz, Matthew P. P.
    Shimizu, Chikako
    Huang, Chiun-Sheng
    Lueck, Hans Joachim
    Beith, Jane
    Tokunaga, Eriko
    Contreras, Jessica Reyes
    de Sant'Ana, Rosane Oliveira
    Wei, Ran
    Shahir, Ashwin
    Nabinger, Sarah C. C.
    Forrester, Tammy
    Johnston, Stephen R. D.
    Harbeck, Nadia
    monarchE Investigators
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    BREAST CARE, 2024, 19 (01) : 27 - 33
  • [38] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [39] Association of endocrine therapy with overall survival in women with hormone receptor-positive, HER2-negative, node-negative breast cancer of favorable histology
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    Ma, Sung Jun
    BREAST JOURNAL, 2020, 26 (10): : 2006 - 2010
  • [40] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345